Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Patent
1997-10-03
1998-07-14
LeGuyader, John L.
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
435 6, 4351721, 536 231, 536 243, 536 241, C12N 1500, C07H 2100, C12Q 168
Patent
active
057806128
ABSTRACT:
The present invention relates to oligonucleotides which are effective inhibitors of disease-associated cellular proliferation. In particular, it relates to the use of oligonulceotides which are substantially complementary to gp130 mRNA sequences. In the form of pharmaceutical compositions, these oligonucleotides are suitable for administration to human subjects for the treatment of abnormal cellular proliferation due to such diseases as cancer, autoimmune disorders and viral infection.
REFERENCES:
patent: 5252723 (1993-10-01), Bhatt
Bangham, et al. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Med. Biol. 13:238-252 (1965).
Caruthers, et al. Chemical synthesis of deoxyoligonucleotides by the phosphoramidite method. Methods in Enzymology 154:287-313 Academic Press, Inc. (1987).
Girasole, et al. Estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteobdlasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. The Journal of Clinical Investigation, Inc. 89:883-891 (1992).
Grossman, et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc. Natl. Acad. Sci. 86:6367-6371. Medical Sciences U.S.A. (1989).
Hibi, et al. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63:1149-1157 Cell Press (1990).
Jilka, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 257:88-91 (1992).
Kishimoto, et al. Interleukin-6 and its receptor: A paradigm for cytokines. Science 258:593-597. (1992).
Klein, et al. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur. Cytokine Net. 1:193-201 (1990).
Levy, et al. Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines. J. Clin. Invest. 88:696-699. (1991).
Majumdar, et al. Stepwise mechanism of HIV reverse transcriptase: Primer function of phosphorothioate oligodeoxynucleotide. Biochemistry, 28:1340-1346. American Chemical Society (1989).
Miles, et al. AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc. Natl. Acad. Sci. 87:4068-4072. Medical Sciences, U.S.A. (1990).
Milligan, et al. Development of antisense therapeutics. Implications for cancer gene therapy. Annals New York Academy of Sciences, 716:228-241 (1994).
Nishimoto, et al. Oncostatin M, Leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, GP130. J. Exp. Med. 179:1343-1347. The Rockefeller University Press (1994).
Scala, et al. Expression of an exogenous interleukin 6 gene in human Epstein Barr virus B cells confers growth advantage and in vivo tumorigenicity. J. Exp. Med. 172:61-68. The Rockefeller University Press (1990).
Shuin, et al. The activity of topoisomerases is related to the grade and stage in human renal cell carcinoma. AntiCancer Research, 14:2621-2626. (1994).
Liu et al., "Interleukin-6 Signal Transducer gp130 Mediates Oncostatin M Signaling", J. Biol. Chem. 267(24): 16763-16766 (1992).
Stec, et al. Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogues of oligodeoxyribonucleotides. J. Am. Chem. Soc. 106:6077-6079 American Chemical Society (1984).
Stein, et al. Phosporthioate oligodeoxynucleotides anti-sense inhibitors of gene expression. Pharmac. Ther. 52:365-384. Pergamon Press Ltd., Great Britian (1992).
Takenawa, et al. Enhanced expression of interleukin-6 in primary human renal cell carcinomas. Journal of the National Cancer Institute. 83:1668-1672 (1991).
Vink, et al. Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor. J. Exp. Med. 172:997-1000. The Rockefeller University Press, (1990).
Uhlmann, et al., "Antisense Oligonucleotides: A New Therapeutic Principle", Chemical Reviews, 90(4):543-584, (Jun. 1990).
Gupta et al., "Silencing of gp130 Gene Expression by Antisense Ribozyme Technology Blocks CNTF Signal Transduction in Embryonal Carcinoma Cells", Society for Neuroscience Abstracts, 19:1-2 (1993).
Stull et al., "Antigene, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects", Pharmaceutical Research 12(4):465-483 (1995).
Gura, T., "Antisense Has Growing Pains", Science 270:575-577 (1995).
Becherer Kathleen Ann
Dattagupta Nanibhushan
Naidu Yathi M.
Cappellari Charles B.
Fisher Carlos A.
Gen-Probe Incorporated
LeGuyader John L.
McGarry Sean
LandOfFree
Oligonucleotides specific for cytokine signal transducer gp130 m does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligonucleotides specific for cytokine signal transducer gp130 m, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligonucleotides specific for cytokine signal transducer gp130 m will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1882931